Added to YB: 2024-04-04
Pitch date: 2024-04-02
LQDA [bullish]
Liquidia Corporation
+127.32%
current return
Author Info
Raging Bull Investments is a lawyer by background who shares actionable investment ideas on value opportunities with a catalyst. Sign up for the newsletter.
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$2.5B
Pitch Price
$15.30
Price Target
20.00 (-42%)
Dividend
N/A
EV/EBITDA
13.88
P/E
18.72
EV/Sales
5.27
Sector
Pharmaceuticals
Category
special_situation
Raging Bull Investments' Largest Winners from Q1: Liquidia Corporation
LQDA: Continued outperformance in 2023 after 130% return last year. Stock mispriced at $12 due to overestimated legal risk. Exercised majority of Jan 25 calls. Injunction lifted, FDA approval path clear for Yutrepia launch. $20 near-term PT, 30% upside. Trimming as event plays out, but holding material portion long-term given enormous upside potential and strong management.
Read full article (2 min)